Stockreport

Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ® for Assessing Measurable Residual Disease in Mantle Cell Lymphoma

Adaptive Biotechnologies Corporation  (ADPT) 
Last adaptive biotechnologies corporation earnings: 2/26 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: adhc.com
PDF clonoSEQ is the first and only assay to receive Medicare coverage for MRD assessment in MCL Coverage leverages new Medicare episode pricing established based on updated [Read more]